-13.3%
TSLA vs MRNA
+945.0%
-958.3%
-39.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -3.3% | +13.1% | -16.4% | -3.9% |
| 7D | -4.7% | +20.6% | -25.4% | -5.5% |
| 30D | +1.7% | +27.1% | -25.4% | +0.5% |
| 3M | +17.7% | +353.4% | -335.7% | +6.2% |
| 6M | -1.9% | +446.3% | -448.1% | -14.8% |
| YTD | -14.3% | +776.2% | -790.5% | -27.4% |
| 1Y | -13.3% | +987.9% | -1,001.2% | -29.5% |
| All | -13.3% | +945.0% | -958.3% | -29.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling